Physician profile
David W Wu
NPI 1023015484
$24,529.18
in general payments reported to CMS, 2019-2025
45 companies · $3,967 in 2025
The $3,967 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,359 · 2020: $2,896 · 2021: $2,992 · 2022: $3,067 · 2023: $3,799 · 2024: $4,449 · 2025: $3,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $78.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,136.68 |
| Education | $78.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $7,018.35 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $2,713.22 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,135.01 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,887.62 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,225.56 | 2019-2025 | |
| Pfizer INC. | $968.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $747.25 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $689.45 | 2021-2025 | Saphnelo, Evusheld |
| Glaxosmithkline, LLC. | $643.45 | 2019-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $638.71 | 2023-2025 | Idacio, Adalimumab-Aacf, Tyenne |
| Alexion Pharmaceuticals, INC. | $578.32 | 2019-2025 | Strensiq, Ultomiris |
| Horizon Therapeutics Plc | $525.75 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $397.74 | 2021-2025 | Lupkynis |
| Organon LLC | $385.56 | 2021-2025 | Hadlima, Renflexis |
| Octapharma USA, INC. | $328.13 | 2023-2025 | Octagam Immune Globulin (Human), Cutaquig, Panzyga |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.